A New, Non-Corrosive, Non-Irritating Treatment for Pediatric Ulcerative Colitis Has Been Submitted for FDA's Orphan Drug Classification

Stock Information for Vitality Biopharma Inc Ordinary Shares

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vitality Biopharma Inc Ordinary Shares

Vitality Biopharma Enters Into $5 Million Equity Line Financing Relationship With Institutional Investor
FDA Grants Vitality Biopharma Orphan Drug Designation for VBX-100 Prodrug
Vitality Biopharma Retains DelMorgan & Co. to Explore Strategic Alternatives
Vitality Biopharma Board Update
Vitality Biopharma Welcomes New Executive Management Team
Vitality Biopharma Co-Founder Dr. Avtar Dhillon Resigns from Board of Directors
Vitality Biopharma Appoints Former Ohio Governor Richard F. Celeste to Board
Vitality Biopharma to Present at the 11th Annual LD Micro Main Event

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.